If you’ve ever taken Zantac for heartburn, you probably didn’t expect it to be at the center of thousands of lawsuits. The controversy began when NDMA (N-Nitrosodimethylamine), a chemical linked to cancer, was discovered in the medication. This finding has ignited an ongoing legal battle. In this article, Ethen Ostroff Law explains what the Zantac lawsuit is all about, breaks down what NDMA is, updates you on the latest developments in the lawsuits, and provide the most recent news for 2025.
Free and confidential. No fee unless we win.
Disclaimer: By submitting the form above and checking the consent box, you agree to our conditions and privacy policy and permit Ethen Ostroff Law to contact you via text messages, phone calls (including automated calls). Standard message rates may apply.
Zantac was the go-to remedy for heartburn and acid reflux for decades. It quickly became a familiar name in medicine cabinets since it hit the market in the 1980s. The key ingredient, ranitidine, is part of a group of drugs known as H2 blockers. They work by cutting down on stomach acid, which can be a real game-changer for those struggling with digestive problems.
At its height, Zantac was incredibly popular. It was the 50th most prescribed drug in the U.S., with over 15 million prescriptions each year. Developed by the European company GlaxoSmithKline and approved in the U.S. in 1983, Zantac’s success was fueled by a big marketing push
Zantac was a popular choice for managing various digestive issues. Here’s where it was commonly used:
Zantac has been produced by several major pharmaceutical companies. The key manufacturers are:
NDMA is a chemical that can be harmful and is known to increase cancer risk. It was found in Zantac at dangerously high levels. NDMA isn’t added to medicines intentionally. It forms when ranitidine, Zantac’s main ingredient, breaks down, especially in high temperatures. Studies showed that NDMA levels in Zantac were much higher than the FDA’s safety limit. This led to a major recall of Zantac products in 2019. The FDA found that long-term exposure to high levels of NDMA could raise the risk of several types of cancer.
Zantac has been linked to several health problems, mostly because of NDMA, a chemical that might cause cancer. Here are some of the main issues:
On April 1, 2020, the FDA asked all manufacturers to pull Zantac and its generic versions from the market. The reason? They discovered NDMA, a chemical that could be dangerous and potentially cause cancer, in these medications. Here’s what you should know:
The recall was a crucial step to protect health, and finding alternative medications is key for anyone affected.
The Zantac lawsuit began when it was found that ranitidine, the main ingredient in Zantac, could break down into NDMA—a chemical linked to cancer. This discovery led many former Zantac users who developed cancer to file lawsuits. In February 2020, these cases were combined into a multidistrict litigation (MDL) called In re: Zantac (Ranitidine) Products Liability Litigation. It’s overseen by Judge Robin L. Rosenberg in the Southern District of Florida. By July 2024, about 2,422 cases were still active. The MDL is still unfolding, with new developments, dismissals, and appeals as those affected pursue justice.
In the ongoing Zantac lawsuits, plaintiffs have made several allegations against the drug’s makers. These claims are central to the legal battle as those affected seek justice:
In the Zantac lawsuits, several pharmaceutical companies are being sued over the cancer risks linked to the drug. The main companies involved are:
As of 2024, the Zantac MDL is still ongoing. Here are some key updates:
August 7, 2024: An Illinois judge declared a mistrial in a case involving allegations that Zantac caused prostate cancer, as the jury was unable to reach a unanimous decision.
August 5, 2024: In Illinois, a jury determined that GSK was not liable for a plaintiff’s colorectal cancer, signaling challenges for similar claims despite ongoing litigation.
July 28, 2024: A settlement was finalized in a prostate cancer case against GSK in Illinois, marking a notable resolution in the ongoing Zantac litigation.
July 20, 2024: Two significant Zantac trials are currently in progress: one involving colorectal cancer and another focusing on prostate cancer, with settlement discussions ongoing.
July 19, 2024: New Zantac trials have started, including a colorectal cancer case and a prostate cancer case, with a recent settlement involving GSK but not Boehringer Ingelheim.
July 18, 2024: A state court trial against GSK and Boehringer Ingelheim has commenced, addressing colorectal cancer claims previously not covered by the MDL.
July 11, 2024: Plaintiffs in the Zantac mass tort case in Philadelphia have requested Judge Joshua Roberts’ recusal due to his wife’s connection with a law firm representing GSK.
July 5, 2024: A new lawsuit has been filed in Delaware accusing Zantac manufacturers of causing severe cancers due to NDMA contamination, with plaintiffs seeking damages for their health issues.
July 2, 2024: GSK has reached a confidential settlement in a prostate cancer lawsuit, adding to the list of resolved Zantac cases.
July 1, 2024: The number of active cases in the Zantac MDL has decreased significantly, shifting focus to state court litigations, especially in Delaware and California.
June 3, 2024: A Delaware judge has mandated that Zantac-related cases be tried in state courts, impacting around 75,000 lawsuits involving major pharmaceutical companies.
May 28, 2024: Zantac jury trials are scheduled in Chicago throughout 2024 and early 2025, with additional trials set for Philadelphia.
May 24, 2024: A Chicago jury found that Zantac was not responsible for a woman’s colon cancer, emphasizing the difficulty in proving such cases.
May 23, 2024: In a Chicago trial, the plaintiff’s attorneys requested $640 million from Zantac manufacturers, highlighting the stakes involved in these cases.
May 19, 2024: A whistleblower lawsuit has been filed against GSK, alleging that the company hid Zantac’s cancer risks, potentially leading to significant financial repercussions.
May 10, 2024: An 89-year-old woman diagnosed with colon cancer in 2015 after using Zantac for nearly 20 years is the latest plaintiff in the ongoing trials.
May 8, 2024: Pfizer has settled over 10,000 Zantac lawsuits, surpassing Sanofi’s recent settlement, with ongoing trials and the potential for more settlements.
May 2, 2024: Angela Valadez’s lawsuit against GSK and Boehringer Ingelheim over Zantac-related colorectal cancer has begun, with a settlement anticipated.
April 22, 2024: Bloomberg reports that recent Zantac settlements averaged around $25,000 per case, significantly lower than initial estimates.
April 4, 2024: Sanofi has settled approximately 4,000 Zantac lawsuits outside Delaware, with specific settlement terms remaining undisclosed.
February 29, 2024: GSK has reached a confidential settlement in a California Zantac lawsuit, opting for a settlement to avoid trial disruptions.
February 2, 2024: GSK settled another Zantac lawsuit before trial, resolving the case with David Browne.
February 1, 2024: Lawyers express cautious optimism about the upcoming ruling by Judge Medinilla, which could impact the future of Zantac litigation.
January 25, 2024: The Daubert hearing in Delaware has concluded, with Judge Vivian L. Medinilla expected to make significant decisions regarding the litigation’s future.
January 23, 2024: The Daubert hearing in Delaware continues, with important implications for the Zantac litigation’s trajectory.
January 19, 2024: The upcoming Daubert hearings in Delaware are set to be crucial for the future of Zantac litigation.
January 14, 2024: An appeal in the Zantac MDL is crucial for the 14,389 plaintiffs, potentially shifting claims to state courts.
On August 7, 2024, the third trial related to Zantac ended in a mistrial. Jurors couldn’t decide if Boehringer Ingelheim was to blame for an Illinois man’s cancer. Martin Gross claimed that NDMA, a harmful chemical in Zantac, caused his prostate cancer. His lawyer plans to retry the case. Boehringer Ingelheim, however, says the evidence shows Zantac doesn’t cause cancer. This mistrial follows two earlier cases, where both ended with decisions in favor of the defense—one for Boehringer Ingelheim and GSK, and one just for GSK. Most Zantac lawsuits are happening in Delaware. In June, a judge allowed over 70,000 cases to proceed, despite the defendants’ attempt to exclude key expert witnesses. The companies are appealing this decision.
If you’re considering joining a Zantac lawsuit, here’s a simple breakdown of who might be eligible:
Regular Use: You need to have taken Zantac (Ranitidine) regularly for at least a year before your cancer diagnosis.
Dosage: Typically, this means using at least 300 mg per week, which generally translates to at least once a week.
Time Frame: You should have used Zantac, whether by prescription or over the counter, between 1984 and 2020.
Age at Diagnosis: You must have been diagnosed with a qualifying cancer at 70 years old or younger.
Timing: Your cancer diagnosis should have occurred after 2022, or within 10 years of your last use of Zantac.
You may qualify if you’ve been diagnosed with one of the following cancers, and meet these additional criteria:
Bladder Cancer: No family history and no catheter use before diagnosis.
Breast Cancer: Only ductal carcinoma qualifies (excludes BRCA1 or BRCA2 mutations).
Colorectal Cancer: No family history or Crohn’s disease before starting Zantac.
Esophageal Cancer: No smoking 25 years before diagnosis and no Barrett’s esophagus before using Zantac.
Lung Cancer: No family history or smoking 25 years before diagnosis.
Liver Cancer: No hepatitis B or C, or Wilson’s disease before or after using Zantac, and no family history.
Pancreatic Cancer: No family history.
Prostate Cancer: No family history and diagnosed at 70 years old or younger.
Stomach/Gastric Cancer: No family history.
You won’t qualify if:
Generic Use Only: You only used generic ranitidine.
Location: You were a resident of Michigan, Tennessee, Louisiana, Kentucky, or Puerto Rico at the time of use or diagnosis.
If you meet these criteria, you might be eligible to pursue a claim.
If you believe you may be eligible for a Zantac claim, consider the following steps:
If you win or settle a Zantac lawsuit, you might receive compensation for:
These funds are meant to cover the various ways Zantac has affected your life.
The Zantac lawsuit has been a turbulent journey. If you’re dealing with a cancer diagnosis linked to Zantac, we can help you. At Ethen Ostroff Law, we’re deeply engaged in these cases and ready to guide you through the process. Let’s help you pursue the justice and compensation you deserve. Contact us today for Zantac update and the support you need.
Some Zantac lawsuits have been settled, with Sanofi agreeing to pay up to $250 million in 2024 and GSK settling several cases confidentially. However, major settlements for other cases might not happen until late 2024 or beyond.
The average payout for Zantac lawsuits isn’t clear yet. Serious cases might exceed $500,000, mid-range cases could be around $250,000, and lower-tier cases might fall between $20,000 and $160,000. A recent $500,000 settlement provides some insight, but the overall average will solidify as more cases are settled.
Yes, the Zantac lawsuit is still active. Thousands of claims are ongoing, and legal proceedings are continuing to address these cases.
To support a Zantac lawsuit, you’ll need to provide medical records showing a cancer diagnosis and evidence of long-term Zantac use.
No, Zantac isn’t safe to take due to its potential NDMA content, a known carcinogen. Consult with your healthcare provider for alternative treatments.
Yes, there are current Zantac class action lawsuits against the manufacturers. These cases are centered on the claim that Zantac contains NDMA, a carcinogen.
His career began in public service as a Surveillance Officer in Maricopa County, where he gained firsthand experience in high-stakes decision-making and developed a deep sense of discipline and accountability. He later served as Chief Operating Officer of a fast-growing law firm, driving efficiency, revenue growth, and team development. Today, Ryan focuses on helping law firms reach their full potential by aligning people, processes, and long-term vision. A strategic thinker and empowering leader, Ryan is passionate about developing others and guiding organizations through meaningful, lasting growth.
Effective Date: 10/15/2026
Ethen Ostroff Law, PLLC (“EOL,” “we,” “us,” or “our”) respects your privacy. If you are reaching out to us after an injury, we know you may be sharing personal details during a hard time. This Privacy Policy explains what information we collect when you visit ethenostrofflaw.com (the “Site”), how we use it, who we share it with, and the choices you have.
This Privacy Policy works together with our Terms of Use. By using the Site, you agree to the practices described here. If you do not agree, please do not use the Site.
Visiting the Site, submitting a form, chatting with us online, or sending us an email does not create an attorney-client relationship. An attorney-client relationship begins only when you and EOL sign a written Retainer Agreement. Until then, information you send us is not protected by attorney-client privilege and is not considered confidential. Please do not send sensitive details about your matter until we have spoken with you.
When you request a free consultation, fill out a form, use our live chat, call, text, or email us, you may give us:
When you visit the Site, we and the third-party tools described in section 8 may automatically collect:
We may share your information with:
If you opt in to text messages, you may receive messages about your inquiry or case. Message frequency varies, and message and data rates may apply. Reply STOP at any time to opt out, or HELP for help. Mobile phone numbers and text message opt-in consent will not be shared with third parties or affiliates for their own marketing purposes.
We do not send the details you type into our intake forms, contact forms, or live chat, such as information about your injury or legal matter, to Google, Meta, TikTok, Reddit, or any other advertising platform.
The Site uses cookies, pixels, and similar tools. A cookie is a small file stored in your browser. A pixel is a small piece of code that loads when you visit a page and sends information about your visit to the company that provides it. We use Google Tag Manager to load and manage these tools.
The table below lists the third-party tools on the Site and what we use them for.
| Provider | What we use it for | Provider privacy policy |
| Google Tag Manager | Loads and manages the other tools listed here. It does not build a profile of you. | policies.google.com/privacy |
| Google Analytics | Understanding how visitors use the Site, such as pages viewed and how they found us. | policies.google.com/privacy |
| Google Ads | Measuring ad conversions and showing our ads to past visitors. | policies.google.com/privacy |
| Meta Pixel (Facebook and Instagram) | Measuring ad performance, showing our ads to past visitors, and reaching similar audiences. | facebook.com/privacy/policy |
| TikTok Pixel | Measuring ad performance, showing our ads to past visitors, and reaching similar audiences. | tiktok.com/legal/privacy-policy |
| Reddit Pixel | Measuring ad performance, showing our ads to past visitors, and reaching similar audiences. | reddit.com/policies/privacy-policy |
| Intaker | Powers the live chat on the Site so you can reach our intake team. | intaker.com |
| OpenWidget (ChatBot.com) | Powers the chat assistant on the Site. | openwidget.com |
| Google reCAPTCHA | Protects our forms from spam and automated abuse. | policies.google.com/privacy |
| Google Maps | Displays maps of our office locations. | policies.google.com/privacy |
These tools may collect the information listed in section 3. If you give us your email address or phone number, a scrambled (hashed) version may be sent to an advertising platform so it can match your visit to an existing account.
Google, Meta, TikTok, and Reddit may combine the information they receive with other data they hold about you and use it under their own privacy policies. You can learn how Google uses information from sites that use its services at policies.google.com/technologies/partner-sites.
Some state privacy laws, including California’s, may treat sharing information through advertising pixels as a “sale” or “sharing” of personal information, or as targeted advertising. Depending on where you live, you may have the right to know what information we hold about you, to ask us to correct or delete it, and to opt out of its sale or sharing. To make a request, contact us using the information in section 15. We may need to verify your identity before we respond. We will not treat you differently for using these rights.
We use reasonable administrative, technical, and physical safeguards to protect your information. No method of sending or storing data over the internet is completely secure, so we cannot guarantee the security of information you send us.
We keep your information as long as we need it for the purposes described in this policy, including to meet legal, ethical, and record-keeping obligations.
The Site is not directed to children under 13, and we do not knowingly collect personal information from them online. If a parent or guardian is contacting us about a child’s injury, the parent or guardian should submit the inquiry.
We may update this policy when we add, change, or remove tools on the Site or change how we handle information. We will post the updated version here and change the effective date above.
If you have questions about this policy or want to make a privacy request, contact us: